Abstract:【Objective】To investigate the relationships between cell adhesion molecule CD44 variant exon6 (CD44v6) and integrin beta 1 with the prognosis of surgical patients with pancreatic cancer. 【Methods】Eightyfive patients with pancreatic cancer who received treatment in our hospital were chosen as the study subjects. The positive expression rates of CD44v6 and integrin beta1 in the pancreatic cancer tissues of the patients with different clinicalpathological features were deterimined. The correlation between the positive expression rates of CD44v6, integrin beta 1 and the levels of tumor markers (CEA, CA199 and CA125) was analyzed. 【Results】The positive expression rates of CD44v6, integrin beta 1, antigen (CEA), carbohydrate antigen 199 (CA199), and carbohydrate antigen 125 (CA125) in the death group were significantly higher than those in the survival group, the difference was statistically significant (P<0.05). Pancreatic cancer patients with old age, lower differentiation, distant metastasis, and invasion of vascular showed higher positive expression rates in CD44v6 and integrin beta1 , the differences were statistical significance (P<0.05). There were no significant differences showing the expression rates of CD44v6 and integrin beta 1 with patient gender, tumor size, and local lymph node invasion (P<0.05). . The positive expression rate of CD44v6 and integrin beta1 in pancreatic cancer patients were significantly positively correlated with CA199, CA125 and CEA, and the difference was statistically significant (P<0.05). 【Conclusion】The high expression of CD44v6 and integrin beta1 contributes to the poor prognosis in patients with pancreatic cancer, and is associated with tumor markers (CEA,CA199 and CA125). It can be used as an important indicator of the prognosis as well.
黄晓华1 高亚洲2. CD44v6、整合素β1对外科根治性胰腺癌患者预后的影响[J]. 医学临床研究, 2016, 33(7): 1261-1267.
HUANG Xiaohua,GAO Yazhou. Effects of CD44v6 and Integrin Beta1 on the Prognosis of Surgical Patients with Pancreatic Cancer. JOURNAL OF CLINICAL RESEARCH, 2016, 33(7): 1261-1267.